The effect of short-term intensive chemotherapy on reactivation of tuberculosis.
BACKGROUND
Various malignancies and cytotoxic chemotherapy have been proposed to increase the risk of reactivation of tuberculosis. Available literature to support this observation is still conflicting. There is scarcity of data from countries with rampant tubercular infection, such as India, in this regard.


METHODS
In the present retrospective analysis, patients with high-grade non-Hodgkin's lymphoma with past history of tuberculosis and have had adequate antitubercular therapy were identified from a Lymphoma Group study. These patients were followed up during cytotoxic chemotherapy and later to assess the risk of reactivation.


RESULTS
A cohort of eight patients with past history of tuberculosis was selected from 141 patients of high-grade non-Hodgkin's lymphoma. The median age was 33.5 years (range, 24-53 years). Median duration between completion of antitubercular treatment and diagnosis of lymphoma was 5 years (range, 1.5-10 years). All patients received cyclical cytotoxic chemotherapy. The median duration of follow up after completion of chemotherapy was 5 years (range, 10 months to 5 years). None of these patients developed reactivation of tuberculosis.


CONCLUSIONS
Cyclical chemotherapy for non-Hodgkin's lymphoma does not lead to reactivation of tuberculosis.
Nair
R
R
Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
Prabhash
K
K
Sengar
M
M
Bakshi
A
A
Gujral
S
S
Gupta
S
S
Parikh
P
P
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin; D003520:Cyclophosphamide; D003561:Cytarabine; D004317:Doxorubicin; D005047:Etoposide; D005260:Female; D006801:Humans; D007069:Ifosfamide; D008228:Lymphoma, Non-Hodgkin / Q000150:complications* / Q000188:drug therapy*; D008297:Male; D015080:Mesna; D008775:Methylprednisolone; D008875:Middle Aged; D008942:Mitoxantrone; D009169:Mycobacterium tuberculosis / Q000502:physiology; D011241:Prednisone; D012189:Retrospective Studies; D014376:Tuberculosis / Q000150:complications*; D014750:Vincristine; D014775:Virus Activation / Q000187:drug effects*
D003561:Cytarabine; D014750:Vincristine; D005047:Etoposide; D004317:Doxorubicin; D003520:Cyclophosphamide; D008942:Mitoxantrone; D015080:Mesna; D002945:Cisplatin; D007069:Ifosfamide; D011241:Prednisone; D008775:Methylprednisolone